Literature DB >> 6221693

Cefoperazone pharmacokinetics in preterm infants.

J A Bosso, G M Chan, J M Matsen.   

Abstract

The elimination pharmacokinetics of cefoperazone, a new cephalosporin, were studied in 15 preterm infants ranging in gestational age from 32 to 36 weeks and in postnatal age from 1 to 6 days. The infants received a single dose of either 50 or 250 mg of cefoperazone per kg by intravenous infusion. Blood samples were collected at specified times after completion of the drug infusion and then assayed for cefoperazone. Pharmacokinetic parameters were determined by noncompartmental analysis. Mean values for plasma half-life, elimination rate constant, apparent steady-state volume of distribution, and total body clearance were 5.53 h, 0.15 h-1, 124 ml/kg, and 36 ml/h per kg, respectively, for the group receiving a 50-mg/kg dose and 5.76 h, 0.14 h-1, 111 ml/kg, and 35 ml/h per kg, respectively, for the group receiving a 250-mg/kg dose. Positive correlations between gestational age and clearance and elimination rate were detected. A 50-mg/kg dose every 12 h ensured adequate serum levels for most of the common neonatal pathogens. Other than a transient rise in eosinophils in four subjects, no adverse effects were noted.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6221693      PMCID: PMC184662          DOI: 10.1128/AAC.23.3.413

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Comparative pharmacokinetics of cefoperazone and cefamandole.

Authors:  S Srinivasan; E L Francke; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

2.  Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.

Authors:  T O Kurtz; D J Winston; J A Hindler; L S Young; W L Hewitt; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

3.  Cefoperazone: absorption, excretion, distribution, and metabolism.

Authors:  K Shimizu
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

4.  Clinical trials with cefoperazone in the field of surgery in Japan.

Authors:  K Shibata
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

5.  Clinical trials with cefoperazone in the field of internal medicine in Japan.

Authors:  K Mashimo; O Kunii
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

6.  Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats.

Authors:  L Balant; P Dayer; M Rudhardt; A F Allaz; J Fabre
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

7.  Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; E H Gerlach; H M Sommers
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

8.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

9.  Disposition kinetics of ethambutol in man.

Authors:  C S Lee; D C Brater; J G Gambertoglio; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-08

10.  Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency.

Authors:  W K Bolton; W M Scheld; D A Spyker; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

View more
  6 in total

1.  Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Authors:  Toshimi Kimura; Keisuke Sunakawa; Nobuo Matsuura; Hiroaki Kubo; Shigehiko Shimada; Kazuo Yago
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  A perspective on new beta-lactam antibiotics in pediatric patients.

Authors:  J D Nelson
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 3.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

4.  Pharmacokinetic evaluation of cefoperazone in infants.

Authors:  M Varghese; A J Khan; K Kumar; W Rosenfeld; H A Schaeffer; H E Evans
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 5.  Pharmacokinetics of cephalosporins in the neonate: a review.

Authors:  Gian Maria Pacifici
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 6.  Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.